drugset / Trial / NCT00485849

A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD

NCT00485849

Phase 4 Completed 12 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the possible response to atomoxetine on the core symptoms of ASD

Timeline

Start
2004-02
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified